Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Korea.
J Allergy Clin Immunol Pract. 2024 Jan;12(1):120-132.e5. doi: 10.1016/j.jaip.2023.09.015. Epub 2023 Sep 27.
Previous studies have suggested that respiratory virus infections may be associated with new-onset asthma. However, whether coronavirus disease 2019 (COVID-19) is associated with an increased risk of new-onset asthma remains unclear.
We aimed to evaluate whether recent COVID-19 increases the risk of new-onset asthma and whether COVID-19 vaccination could mitigate this risk.
We constructed 3 different study designs using the Korean National Health Insurance claim-based database: study 1: COVID-19-diagnosed subjects (COVID-19 cohort) and their matched controls; study 2: COVID-19-vaccinated subjects (vaccination cohort) and their matched controls; and study 3: vaccination cohort and their matched controls, excluding subjects diagnosed with COVID-19.
In study 1, 1.6% of the COVID-19 cohort and 0.7% of the matched cohort developed new-onset asthma, with incidences of 31.28 and 14.55 per 1,000 person-years, respectively (P < .001). The COVID-19 cohort had a higher risk of new-onset asthma (adjusted hazard ratio [aHR] 2.14; 95% CI 1.88-2.45) than matched controls. In study 2, the vaccination cohort had a lower risk of new-onset asthma than the matched controls (aHR 0.82; 95% CI 0.76-0.89). However, among subjects without a COVID-19 diagnosis, COVID-19 vaccination was not associated with a reduced risk of new-onset asthma in study 3 (aHR 0.95; 95% CI 0.87-1.04). In subgroup analysis, the risk of new-onset asthma was significantly lower in fully vaccinated subjects and higher in older subjects and in those with diabetes mellitus than in their counterparts.
The COVID-19 was associated with a higher incidence of new-onset asthma, which might be preventable by COVID-19 vaccination.
先前的研究表明,呼吸道病毒感染可能与新发哮喘有关。然而,COVID-19 是否会增加新发哮喘的风险尚不清楚。
我们旨在评估 COVID-19 近期感染是否会增加新发哮喘的风险,以及 COVID-19 疫苗接种是否可以降低这种风险。
我们使用韩国国家健康保险索赔数据库构建了 3 种不同的研究设计:研究 1:COVID-19 确诊患者(COVID-19 队列)及其匹配对照;研究 2:COVID-19 疫苗接种者(疫苗接种队列)及其匹配对照;和研究 3:疫苗接种队列及其匹配对照,排除诊断为 COVID-19 的患者。
在研究 1 中,COVID-19 队列中有 1.6%的患者和匹配队列中有 0.7%的患者新发哮喘,发病率分别为 31.28 和 14.55 例/1000 人年(P<.001)。COVID-19 队列新发哮喘的风险高于匹配对照组(调整后的危险比[aHR]2.14;95%CI1.88-2.45)。在研究 2 中,疫苗接种队列新发哮喘的风险低于匹配对照组(aHR 0.82;95%CI0.76-0.89)。然而,在没有 COVID-19 诊断的患者中,COVID-19 疫苗接种与研究 3 中新发哮喘风险降低无关(aHR 0.95;95%CI0.87-1.04)。在亚组分析中,完全接种疫苗的患者新发哮喘的风险显著降低,而年龄较大的患者和患有糖尿病的患者的风险则较高。
COVID-19 与新发哮喘的发生率较高相关,而 COVID-19 疫苗接种可能预防这种情况。